- Home
- SOL vs LCTX Comparison
SOL vs LCTX Comparison
Compare SOL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- LCTX
- Stock Information
- Founded
- SOL 2005
- LCTX 1990
- Country
- SOL United States
- LCTX United States
- Employees
- SOL N/A
- LCTX N/A
- Industry
- SOL Semiconductors
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOL Technology
- LCTX Health Care
- Exchange
- SOL Nasdaq
- LCTX Nasdaq
- Market Cap
- SOL 94.9M
- LCTX 107.3M
- IPO Year
- SOL 2008
- LCTX N/A
- Fundamental
- Price
- SOL $1.91
- LCTX $1.00
- Analyst Decision
- SOL Strong Buy
- LCTX Strong Buy
- Analyst Count
- SOL 2
- LCTX 5
- Target Price
- SOL $4.50
- LCTX $4.20
- AVG Volume (30 Days)
- SOL 388.5K
- LCTX 4.2M
- Earning Date
- SOL 08-19-2025
- LCTX 08-07-2025
- Dividend Yield
- SOL N/A
- LCTX N/A
- EPS Growth
- SOL N/A
- LCTX N/A
- EPS
- SOL N/A
- LCTX N/A
- Revenue
- SOL $85,621,000.00
- LCTX $9,557,000.00
- Revenue This Year
- SOL N/A
- LCTX N/A
- Revenue Next Year
- SOL $45.37
- LCTX $232.66
- P/E Ratio
- SOL N/A
- LCTX N/A
- Revenue Growth
- SOL N/A
- LCTX 19.42
- 52 Week Low
- SOL $1.04
- LCTX $0.37
- 52 Week High
- SOL $3.00
- LCTX $1.15
- Technical
- Relative Strength Index (RSI)
- SOL 61.62
- LCTX 66.90
- Support Level
- SOL $1.84
- LCTX $0.93
- Resistance Level
- SOL $1.95
- LCTX $1.06
- Average True Range (ATR)
- SOL 0.03
- LCTX 0.11
- MACD
- SOL -0.00
- LCTX -0.00
- Stochastic Oscillator
- SOL 67.91
- LCTX 70.00
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has globalised Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. Majority of revenue is From Electricity Generation. The company operates in China, USA, Germany, UK, Spain, France, Poland, Italy, Hungary, Luxembourg. Majority of revenue is from Italy.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.